Relmada Therapeutics, Inc.
RLMD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001553643
In the last 90 days, Relmada Therapeutics, Inc. insiders filed 2 open-market purchases and 0 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $693.7M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $455.5M
- Insider buysLast 90 days, $1.67M in total
- 2
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +24 vs. previous quarter
- 126
- 13F valueReported value at the end of Q2 2026
- $693.7M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$57.4M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q2 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 10.8M
- Shares sold short
- Change
- −1.34M
- −11.0% vs. previous
- Days to cover
- 6.36
- At average daily volume
Superinvestors holding RLMD, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding RLMD at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Relmada Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 (view filing)7:30 AM ET | Sep 9-10 | 2 days | Shenouda MagedChief Financial Officer | PPurchase | +200.0K | $4.22 | +$844.0K | +25.0%1.00M after | 2 lots |
| Sep 11, 2026 (view filing)7:30 AM ET | Sep 9-10 | 2 days | Traversa SergioChief Executive Officer | PPurchase | +200.0K | $4.14 | +$828.0K | +15.4%1.50M after | 2 lots |
| Dec 16, 2025 (view filing) | Dec 15 | 1 day | Traversa SergioChief Executive Officer | PPurchase | +27.5K | $4.12 | +$113.3K | +2.2%1.30M after | |
| Dec 16, 2025 (view filing) | Dec 15 | 1 day | Shenouda MagedChief Financial Officer | PPurchase | +11.7K | $4.12 | +$48.1K | +1.5%800.0K after | |
| Nov 6, 2025 (view filing) | Nov 5 | 1 day | Ence ChuckCAO and COO | PPurchase | +136.0K | $2.20 | +$299.2K | +50.8%403.9K after | |
| Nov 6, 2025 (view filing) | Nov 5 | 1 day | Traversa SergioChief Executive Officer | PPurchase | +272.5K | $2.20 | +$599.5K | +27.3%1.27M after | |
| Nov 6, 2025 (view filing) | Nov 5 | 1 day | Shenouda MagedChief Financial Officer | PPurchase | +500.0K | $2.20 | +$1.10M | +173.4%788.3K after | |
| Nov 6, 2025 (view filing) | Nov 5 | 1 day | Kelly Paul EdwardChief Operating Officer | PPurchase | +90.0K | $2.20 | +$198.0K | +21.8%502.3K after | |
| Aug 28, 2025 (view filing) | Aug 26-28 | 2 days | Traversa SergioChief Executive Officer | PPurchase | +266.0K | $0.6696 | +$178.1K | +36.2%1.00M after | 3 lots |
| May 20, 2025 (view filing)6:03 PM ET | May 16 | 4 days | Kelly Paul EdwardChief Operating Officer | PPurchase | +200.0K | $0.4303 | +$86.1K | +94.2%412.3K after |
Top 10 13F holders, Q2 2026
See all 126 holdersThe largest institutional positions in Relmada Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 11,164,803 | $77.3M | 0.03% | +11,164,803 | New |
| BlackRock, Inc. | 7,426,780 | $51.4M | 0.00% | +6,137,230+475.9% | Added |
| Squadron Capital Management LLC | 7,350,000 | $50.9M | 17.41% | −1,124,571−13.3% | Reduced |
| VR Adviser, LLC | 6,844,305 | $47.4M | 1.44% | +2,000,925+41.3% | Added |
| Spruce Street Capital LP | 6,391,328 | $44.2M | 8.68% | +129,214+2.1% | Added |
| Adage Capital Partners GP, L.L.C. | 4,763,158 | $33.0M | 0.05% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 4,460,210 | $30.9M | 0.00% | +1,383,640+45.0% | Added |
| Jones Hill Capital LP | 3,655,075 | $25.3M | 5.38% | +3,312,323+966.4% | Added |
| OrbiMed Advisors LLC | 3,631,195 | $25.1M | 0.48% | −1,084,669−23.0% | Reduced |
| State Street Corp | 2,517,550 | $17.4M | 0.00% | +2,160,510+605.1% | Added |
Holders of 5% or more of RLMD
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Relmada Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Janus Henderson Group PLC | 13G | 10.10%7.44M shares | New | Feb 6, 20261 filing | Feb 6, 2026 | SEC |
| BlackRock, Inc. | 13G | 7.00%7.35M shares | New | Jul 29, 20261 filing | Jul 29, 2026 | SEC |
| Squadron Capital Management LLC | 13G/A | 7.00%7.35M shares | −2.90 ppfrom 9.90% | May 1, 20254 filings | Aug 14, 2026 | SEC |
| Venrock Healthcare Capital Partners III, L.P. | 13G | 6.20%6.51M shares | New | Jun 9, 20261 filing | Jun 9, 2026 | SEC |
| Spruce Street Capital LP | 13G | 5.57%4.09M shares | New | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
Politician trades
All politician trades in RLMD1 member of Congress reported 2 trades in Relmada Therapeutics, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Jan 20, 2023 |  Chris Jacobs House · NY | Sell | $1K-$15K |
| Dec 12, 2022 | Chris Jacobs House · NY | Buy | $1K-$15K |
House · NY · Jan 20, 2023
Sell$1K-$15K
House · NY · Dec 12, 2022
Buy$1K-$15K